News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
327,574 Results
Type
Article (19592)
Company Profile (139)
Press Release (307843)
Section
Business (105197)
Career Advice (867)
Deals (18491)
Drug Delivery (90)
Drug Development (50629)
Employer Resources (79)
FDA (7628)
Job Trends (7716)
News (185502)
Policy (17290)
Tag
Academia (726)
Alliances (27702)
Alzheimer's disease (561)
Approvals (7598)
Artificial intelligence (81)
Bankruptcy (170)
Best Places to Work (5503)
Biosimilars (67)
Biotechnology (62)
Cancer (547)
Cardiovascular disease (60)
Career advice (704)
Cell therapy (83)
Clinical research (41730)
Collaboration (213)
Compensation (69)
COVID-19 (1073)
C-suite (60)
Data (622)
Diabetes (94)
Diagnostics (1716)
Drug pricing (91)
Earnings (38286)
Employer resources (73)
Events (47585)
Executive appointments (199)
FDA (7889)
Funding (155)
Gene therapy (87)
GLP-1 (484)
Government (1797)
Healthcare (5857)
Infectious disease (1121)
Inflammatory bowel disease (67)
Interviews (114)
IPO (7290)
Job creations (2430)
Job search strategy (645)
Layoffs (252)
Legal (4078)
Lung cancer (97)
Manufacturing (128)
Medical device (1949)
Medtech (1952)
Mergers & acquisitions (11238)
Metabolic disorders (325)
Neuroscience (725)
NextGen Class of 2024 (2347)
Non-profit (904)
Northern California (665)
Obesity (209)
Opinion (174)
Patents (70)
People (32895)
Pharmaceutical (75)
Phase I (13003)
Phase II (17664)
Phase III (14222)
Pipeline (283)
Podcasts (56)
Policy (70)
Postmarket research (1609)
Preclinical (4566)
Radiopharmaceuticals (156)
Rare diseases (138)
Real estate (3166)
Regulatory (12117)
Research institute (817)
Resumes & cover letters (138)
Southern California (615)
Startups (2005)
United States (6111)
Vaccines (210)
Weight loss (183)
Date
Today (69)
Last 7 days (362)
Last 30 days (1853)
Last 365 days (17928)
2024 (16405)
2023 (19637)
2022 (25874)
2021 (26643)
2020 (24877)
2019 (20064)
2018 (15594)
2017 (17258)
2016 (16208)
2015 (18804)
2014 (14793)
2013 (12556)
2012 (13486)
2011 (13823)
2010 (12739)
Location
Africa (406)
Asia (24514)
Australia (3146)
California (1495)
Canada (746)
China (149)
Colorado (64)
Connecticut (60)
Europe (50458)
Florida (211)
Illinois (146)
Indiana (115)
Japan (56)
Maryland (228)
Massachusetts (1267)
Minnesota (88)
New Jersey (578)
New York (439)
North Carolina (357)
Northern California (665)
Ohio (63)
Pennsylvania (369)
South America (603)
Southern California (615)
Texas (194)
Washington State (145)
327,574 Results for "sichuan kelun pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
AACR: Merck, Kelun’s Anti-TROP2 ADC Shows Early Promise in Gastric Cancer
Merck and Kelun-Biotech’s antibody-drug conjugate achieved a 22% objective response rate and 80.5% disease control rate in heavily pretreated patients with gastric or gastroesophageal junction cancer.
April 10, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference
The 42nd J.P. Morgan Annual Healthcare Conference 2024 is taking place on January 8-11 at San Fracisco, USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. senior management team participated in the conference.
January 11, 2024
·
3 min read
Press Releases
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
October 31, 2024
·
4 min read
Press Releases
Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress
September 30, 2024
·
7 min read
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC
August 20, 2024
·
5 min read
Press Releases
Three Study Results Abstracts From Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) At 2024 ESMO Released Today
September 9, 2024
·
9 min read
BioMidwest
Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University
Rafarma Pharmaceuticals - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023.
December 11, 2023
·
3 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
1 of 32,758
Next
